Acumen Pharmaceuticals discovers and develops targeted therapies for the treatment of Alzheimer's disease. Co.'s primary drug candidate, ACU193, is a humanized monoclonal antibody which selectively targets amyloid-beta oligomers. Co. holds exclusive rights to the program. We show 5 historical shares outstanding datapoints in our coverage of ABOS's shares outstanding history.
Understanding the changing numbers of ABOS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ABOS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ABOS by allowing them to research ABOS shares outstanding history
as well as any other stock in our coverage universe. |
Free ABOS Email Alerts:
Video: Shares Outstanding Importance
